

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **CHINA HEALTHWISE HOLDINGS LIMITED**

**中國智能健康控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 348)**

### **INSIDE INFORMATION EXPECTED SIGNIFICANT DECREASE IN LOSS**

This announcement is made by China Healthwise Holdings Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provision (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary assessment of the Group’s unaudited consolidated management accounts for the year ended 31 December 2025 (“**FY2025**”), the Group expects to record a loss attributable to owners of the Company within the range of approximately HK\$1.8 million to HK\$3.4 million, representing a significant decrease in loss of approximately 92% to 96% as compared to the loss attributable to owners of the Company of approximately HK\$40 million for the year ended 31 December 2024 (“**FY2024**”).

The expected significant decrease in loss attributable to owners of the Company was primarily attributable to (1) an unrealised fair value gain on financial assets at fair value through profit or loss of approximately HK\$25 million for FY2025, as compared to an unrealised fair value loss of approximately HK\$4 million for FY2024; and (2) a reversal of impairment loss recognised under the expected credit loss model in respect of the Group’s loan receivables and trade and other receivables of approximately HK\$4 million for FY2025, as compared to an impairment loss of approximately HK\$2 million for FY2024.

The Board wishes to emphasise that the information contained in this announcement is based on the preliminary assessment of the latest information currently available to the Board, which have not been audited or reviewed by the Company’s independent auditor. As at the date of this announcement, the Company’s annual results for FY2025 have not been finalised and are still subject to possible adjustments and allowances, and may be significantly different from the information disclosed herein. The annual results of the Company for FY2025 are scheduled to be approved and announced by the Board on 27 March 2026.

**Shareholders and potential investors are advised to exercise caution in dealing in the shares of the Company.**

By Order of the Board  
**China Healthwise Holdings Limited**  
**Lei Hong Wai**  
*Chairman and Executive Director*

Hong Kong, 24 March 2026

*As at the date of this announcement, the executive Directors are Mr. Lei Hong Wai (Chairman), Mr. Cheung Kwok Wai Elton (Vice Chairman), Mr. Leung Alex, Ms. Lo Ming Wan and Mr. Yuan Huixia; and the independent non-executive Directors are Mr. Fung Wai Ching, Mr. Lai Hok Lim and Mr. Tsang Chin Pang.*